NutriStack
Berberine and Lovastatin, a caution.
Lovastatin is highly dependent on CYP3A4 metabolism, and berberine has human evidence of inhibiting CYP3A4 after repeated dosing. This creates a plausible risk of increased lovastatin exposure and muscle toxicity, especially with high lovastatin doses or additional CYP3A4 inhibitors. Human clinical outcome data for this exact combination are limited.
One pair, every claim cited. The two substances, the type, the mechanism, the recommendation, and the primary literature.
Same shape as the other 1,729 pairs in the public database.
From the interaction database
What the row says.
Every entry follows the same shape: what is happening, the mechanism, the recommendation, and the primary literature.
At a glance
- Substances
- Berberine and Lovastatin
- Pair type
- Caution
- Evidence (highest tier)
- Emerging
- Source citations
- 3 sources
- Stack Score effect
- −5 to your Stack Score (per scored caution row).
- Scope
- Supplement × Prescription
- Last verified
- May 30, 2026
Caution · Emerging evidence
Caution
What is happening. Lovastatin is highly dependent on CYP3A4 metabolism, and berberine has human evidence of inhibiting CYP3A4 after repeated dosing. This creates a plausible risk of increased lovastatin exposure and muscle toxicity, especially with high lovastatin doses or additional CYP3A4 inhibitors. Human clinical outcome data for this exact combination are limited.
Mechanism. Berberine can reduce CYP3A4 activity in humans. Lovastatin undergoes extensive CYP3A4-mediated first-pass metabolism, so reduced enzyme activity can raise systemic statin exposure and myopathy risk.
Recommendation. Avoid adding high-dose berberine to lovastatin unless your prescriber agrees and knows your full medication list. Report muscle pain, weakness, dark urine, or marked fatigue promptly.
Sources (3)
- Guo Y, Chen Y, Tan ZR, Klaassen CD, Zhou HH. Repeated administration of berberine inhibits cytochromes P450 in humans. Eur J Clin Pharmacol. 2012;68(2):213-217. PMID 21870106
- Feng P, Zhao L, Guo F, Zhang B, Fang L, Zhan G, et al. The enhancement of cardiotoxicity that results from inhibiton of CYP 3A4 activity and hERG channel by berberine in combination with statins. Chem Biol Interact. 2018;293:115-123. PMID 30086269
- Hirota T, Fujita Y, Ieiri I. An updated review of pharmacokinetic drug interactions and pharmacogenetics of statins. Expert Opin Drug Metab Toxicol. 2020;16(9):809-822. PMID 32729746
Stack Score
How this pair moves the number.
Effect on the composite score
If both Berberine and Lovastatin are in the same stack, this pair applies −5 to your Stack Score (per scored caution row).
The full algorithm, the clamping rules, and four worked stacks are documented at /methodology/stack-score.
Check your full routine
One pair was the worked example. NutriStack runs every pair in your stack at once.
Drop in your supplements and prescriptions and the public database surfaces every interaction, synergy, timing rule, and contraindication, every one linked to its primary source.